MSD

Contact information
- A. Health Biotechnology
- Areas of activity
- Biodrugs
- Vaccines
- Therapeutic areas
- Analgesia & Pain
- Dermatology
- Musculoskeletal system
- Cardiovascular diseases and circulatory system
- Infectious diseases
- Inflammatory diseases
- Gynaecology and obstetrics
- Immunology
- Ophtalmology and optometry
- Oncology
- Blood and lymphatic system
- Digestive system and hepatology
- Central nervous system
- Respiratory and pulmonary system
- Metabolic disorders / Endocrinology
Today's MSD is working to help the world be well. Through our medicines, vaccines, biologic therapies, and consumer and animal products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to health care through far-reaching programs that donate and deliver our products to the people who need them.
Corporate responsibility
Corporate responsibility is our daily commitment to save and improve lives by discovering better ways to make a difference in everything we do.
MSD pipeline has over 20 promising late-stage candidates spanning the stages of life, and we have a presence in more than 100 countries around the world, including emerging markets. MSD also publishes unbiased health information as a non-profit service.
To visit MSD pipeline:
http://www.merck.com/research/pipeline/home.html?WT.svl=content
Scientific discovery and development have always been the cornerstones of our company. Today, we conduct research in a broad range of therapeutic categories including cardiovascular disease, infectious diseases, vaccines, cancer, neurology and womens health. And, to help achieve our goal of saving and improving lives around the world, we are expanding our capabilities in new areas, such as biologics.
Biotech Sanitaria
Product / Service | Type | Therapeutic area | Development phase |
---|---|---|---|
ZINPLAVA | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
Zilovertamab Vedotin (MK2140) | Biodrugs/ Drugs | Oncología | P II |
ZERBAXA | Biodrugs/ Drugs | Enfermedades infecciosas | P II |
ZERBAXA | Biodrugs/ Drugs | Sistema respiratorio y pulmonar | P I |
ZERBAXA | Biodrugs/ Drugs | Enfermedades infecciosas | P I |
Vericiguat | Biodrugs/ Drugs | Enfermedades cardiovasculares y sistema circulatorio | P III |
Vaxelis | Vaccines | Enfermedades infecciosas | P III |
V-937/Pembrolizumab | Biodrugs/ Drugs | Oncología | P II |
RSV vaccine | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
RIG-I | Biodrugs/ Drugs | Oncología | P I |
RECARBRIO (mk7655A) | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
Prevymis (Letermovir) | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
Prevymis (Letermovir) | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
Prevymis (Letermovir) | Biodrugs/ Drugs | Enfermedades infecciosas | P II |
Posaconazole | Biodrugs/ Drugs | Enfermedades infecciosas | P III |
Posaconazole | Biodrugs/ Drugs | Enfermedades infecciosas | P I |
Pneumococcal vaccine polyvalent | Vaccines | Enfermedades infecciosas | P III |
Pembrolizumanb/Enfortumab | Biodrugs/ Drugs | Oncología | P III |
pembrolizumab+MK6482+lenvatinib / MK1308A + lenvatinib | Biodrugs/ Drugs | Oncología | P III |
Pembrolizumab+MK5890 o MK4830 o Lenvatinib + Etoposido/Platinum | Biodrugs/ Drugs | Oncología | P II |
Pembrolizumab+ MK7684 (Vibostolimab) | Biodrugs/ Drugs | Oncología | P II |
Pembrolizumab/Olaparib | Biodrugs/ Drugs | Oncología | P III |
Pembrolizumab/Olaparib | Biodrugs/ Drugs | Oncología | P III |
Pembrolizumab/Olaparib | Biodrugs/ Drugs | Oncología | P III |
Pembrolizumab/Olaparib | Biodrugs/ Drugs | Oncología | P III |